Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy that is associated with repetitive head impacts or exposure to blast waves. First described as punch-drunk syndrome and dementia pugilistica in retired boxers [1] [2] [3] , CTE has since been identified in former participants of other contact sports, ex-military personnel and after physical abuse [4] [5] [6] [7] . No disease-modifying therapies currently exist, and diagnosis requires an autopsy. CTE is defined by an abundance of hyperphosphorylated tau protein in neurons, astrocytes and cell processes around blood vessels 8, 9 . This, together with the accumulation of tau inclusions in cortical layers II and III, distinguishes CTE from Alzheimer's disease and other tauopathies 10, 11 . However, the morphologies of tau filaments in CTE and the mechanisms by which brain trauma can lead to their formation are unknown. Here we determine the structures of tau filaments from the brains of three individuals with CTE at resolutions down to 2.3 Å, using cryo-electron microscopy. We show that filament structures are identical in the three cases but are distinct from those of Alzheimer's and Pick's diseases, and from those formed in vitro [12] [13] [14] [15] . Similar to Alzheimer's disease 12, 14, [16] [17] [18] , all six brain tau isoforms assemble into filaments in CTE, and residues K274-R379 of three-repeat tau and S305-R379 of four-repeat tau form the ordered core of two identical C-shaped protofilaments. However, a different conformation of the β-helix region creates a hydrophobic cavity that is absent in tau filaments from the brains of patients with Alzheimer's disease. This cavity encloses an additional density that is not connected to tau, which suggests that the incorporation of cofactors may have a role in tau aggregation in CTE. Moreover, filaments in CTE have distinct protofilament interfaces to those of Alzheimer's disease. Our structures provide a unifying neuropathological criterion for CTE, and support the hypothesis that the formation and propagation of distinct conformers of assembled tau underlie different neurodegenerative diseases.
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We extracted tau filaments from the temporal cortices of a former professional American football player (case 1) and two ex-professional boxers (cases 2 and 3) with neuropathologically confirmed diagnoses of CTE. Perivascular hyperphosphorylated tau (AT8-positive) was present in neurons, astroglia and cell processes in the depths of cortical sulci and around blood vessels more generally, especially in the subependymal region (Fig. 1a, b) , and there were abundant tau inclusions composed of assembled, hyperphosphorylated three-repeat and four-repeat tau isoforms in superficial cortical layers (Fig. 1c , Extended Data Fig. 1, Methods) .
Negative-stain electron microscopy revealed a predominant helical filament type in all three cases, which comprised about 90% of filaments and had projected widths of 20-25 nm and crossover spacings of 65-80 nm (Fig. 1d , type I tau filaments). These filaments differed from the paired helical and straight filaments of Alzheimer's disease (which consist of three-repeat and four-repeat tau) 12, 14 , the narrow and wide Pick filaments of Pick's disease (which are made only of three-repeat tau) 13 and filaments assembled from either recombinant three-repeat or four-repeat tau using heparin 15 . The remaining filaments resembled paired helical filaments, and had pronounced helical twists that resulted in projected widths of 15-30 nm (Fig. 1d, type II tau filaments) .
Immunoblotting of the sarkosyl-insoluble fractions from the temporal cortex showed a pattern of tau bands similar to that in Alzheimer's disease 17, 18 in the former footballer and, as previously shown 16 , in both former boxers, which is consistent with the presence of all six brain tau isoforms in a hyperphosphorylated state 17, 18 (Extended Data Fig. 1d ). Immunogold negative-stain electron microscopy indicated that, in all three cases of CTE, the sequences within the structured core of filaments contain R3 and R4 of tau (as in paired helical and straight filaments 12, 14 ) and that the N-terminal parts of R1 and R2 form part of an unstructured fuzzy coat 19 (Extended Data Fig. 2 ). We used cryo-electron microscopy (cryo-EM) and helical reconstruction in RELION 20 to determine the structures of the tau filaments of CTE (Fig. 2, Extended Data Fig. 3a , Extended Data Table 1 ). In all three cases, the predominant type I tau filaments comprised pairs of identical protofilaments related by an approximate 2 1 helical symmetry (Fig. 2a, Extended Data Fig. 3a) . The protofilament structure (CTE fold) is reminiscent of the C-shaped Alzheimer fold 12 , but adopts a more open conformation. Most notably, additional density-which is not present in the Alzheimer fold-is surrounded by the density of the tau protein chain within the ordered core. Three-dimensional classification of the minority type II tau filaments from case 1 revealed that this population comprised two kinds of filament. About 75% of these filaments were composed of pairs of the same protofilament as in CTE type I tau filaments (including the extra density), also related by an approximate 2 1 helical symmetry but with a different protofilament interface (Fig. 2b, Extended Data Fig. 3a) . We refer to these filaments as CTE type II tau filaments. The remaining filaments were identical to paired helical filaments (Extended Data Fig. 3b ). For case 2, 3D classification identified only CTE type II tau filaments in the minority population (Fig. 2b) . For case 3, too few filaments were present to perform 3D classification or refinement of the minority population. As in paired helical and straight filaments 14 , we observed weaker densities that extend from the N-and C-terminal regions of the core of all the filament types, as well as densities that border the solvent-exposed side chains of K317 and K321, H362 and K369, and K369 and K375. We conclude that over 97% of tau filaments in CTE comprise pairs of protofilaments with a conserved fold that is distinct from the Alzheimer and Pick folds.
By correcting for three-and fourfold astigmatism in the case 1 dataset (Methods), we obtained a map of the CTE type I tau filaments at a resolution of 2.3 Å (Fig. 2c, Extended Data Fig. 4 ). We identified densities that correspond to peptide-group oxygen atoms, ordered solvent molecules and alternative conformations of amino acid side chains (Extended Data Fig. 5 ). Consequently, we could build and stereochemically refine an atomic model with unprecedented accuracy for amyloid filaments (Fig. 2c) . This revealed that, similar to the Alzheimer Letter reSeArCH fold, the CTE fold is formed from residues K274-R379 of three-repeat tau and S305-R379 of four-repeat tau. The topology and secondary structure elements of the CTE fold are also similar to the Alzheimer fold 12 ( Fig. 3a) . These may be common features of filaments composed of both three-and four-repeat tau in the human brain. Eight β-strands (β1 to β8) pack against each other to form a combined cross-β and β-helix fold: β1 and β2 engage in anti-parallel cross-β packing against β8; β3 packs against β7; and β4, β5 and β6 form a triangular β-helix that turns the main chain back on itself (Extended Data Fig. 6 ). We resolved alternative conformations for the stretch of solvent-exposed side chains in the β-helix (β4) with alternating positive and negative charges (Extended Data Fig. 5c ), which demonstrated intramolecular charge interactions that compensate for stacked side chains with identical charges, as hypothesized for the Alzheimer fold 12 . We also identified density that corresponded to ordered solvent molecules (which we interpreted as water) between the backbone of V313 in β1 and the side chains of H374 and E372 of β8; between the side chain of S320 and the backbone of K321 of β2 and that of G365; between the backbones of G333 and G335 and the side chain of S356 in β7; and between the backbones of K337 and D348 in the β-helix (Extended Data Fig. 5b ). It is likely that other tau filament folds, including those of Alzheimer's and Pick's diseases, incorporate ordered solvent molecules in a similar manner.
The 3.4 Å-resolution map of the CTE type II tau filaments from case 1 also enabled us to generate a stereochemically refined atomic model (Fig. 2d, Extended Data Fig. 4 ). This showed that CTE type I and CTE type II tau filaments are ultrastructural polymorphs that have a common protofilament structure, but with different protofilament . This interface is not compatible with phosphorylation of S324, which has previously been reported in Alzheimer's disease 21 , and may explain why tau filaments with this protofilament interface are not observed in Alzheimer's disease. The protofilament interface of CTE type II tau filaments is formed by the 331 KPGGGQVE 338 motif that also forms the paired-helical-filament interface in Alzheimer's disease 12, 14 . However, whereas the 332 PGGG 335 motif adopts an extended conformation in the Alzheimer fold-in which all three glycine residues form hydrogen bonds 12 -it has a kinked conformation in CTE type II filaments, in which only G334 and G335 contribute to hydrogen bonding. Similar to paired helical filaments 14 , the side chain of K331 interacts with those of Q336 and E338 on the other protofilament. It is possible that the presence of a less stable interface accounts for the lower abundance of CTE type II than type I filaments.
A different β-strand packing in the β-helix motif than that in the Alzheimer fold creates a hydrophobic cavity that courses through CTE type I and II tau filaments (Fig. 3a, b ). In the Alzheimer fold, the interior-facing side chains of the β-helix pack tightly against each other, which leaves no space to incorporate additional mass 12 . The distance between the C α atoms of L344 and I354 is 11.5 Å in the Alzheimer fold and 17 Å in the CTE fold (Fig. 3c ). This cavity is fully occupied by an extra density in the CTE fold (Fig. 3d) . The repacked β-helix coincides with the kink in the preceding 332 PGGG 335 motif, which is compensated for by a different conformation of the 353 
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357 motif than in the Alzheimer fold (Fig. 3a) . In the CTE fold, the side chain of S356 points inward and that of L357 points outward (opposite to their orientations in the Alzheimer fold), which creates a tighter turn and precludes phosphorylation of S356. In addition, minor conformational adjustments tighten the turn formed by 341 
SEKL
344 between β4 and β5 and relax the turn formed by 346 
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350 between β5 and β6, compared to the Alzheimer fold. Overall, these conformational changes swivel the β-helix motif relative to the common cross-β packing stacks in the CTE fold, which yields a more-open fold than in the tau filaments of Alzheimer's disease.
The extra density in the cavity is as strong as that of tau, which implies near-stoichiometric occupancies (Fig. 2) . This extra density is surrounded by the hydrophobic side chains of V339, L344, F346, V350 and I354, and the hydroxyl groups of S341 and S352, indicating that the extra density is primarily hydrophobic (Fig. 3c, d ). This density does not connect to the density for the tau molecules, which suggests that it is not covalently linked to tau, and we found no evidence by mass spectrometry of post-translational modifications of either S341 or S352.
The extra density appears as an elliptical rod that has cross-sectional dimensions similar to those of the neighbouring side chain of F346. Despite the resolution of our reconstruction, the extra density has few features along the helical axis and attempts to resolve it in this direction by performing refinements with a larger helical rise were unsuccessful. This is consistent with the observation that power spectra of individual filaments, as well as the average power spectra of all segments used for refinement, show only a layer line at 4.7 Å. The extra density may correspond to hydrophobic molecules that fill the cavity end-to-end, and span a variable number of tau molecules along the helical axis. RNA and sulfated glycosaminoglycans (such as heparin), which induce tau aggregation in vitro [22] [23] [24] , are too hydrophilic and too large to occupy the cavity. Candidate molecules include non-polar sterols and sterol derivatives, as well as fatty acids with one or two aliphatic chains and their derivatives.
The CTE fold is the only known amyloid structure to date to incorporate non-proteinaceous molecules, which suggests a novel basis for conformer formation and propagation that is not dependent only on protein. The buried nature of these molecules, their high occupancy and their presence in the majority of filaments at end-stage disease indicate that they are continuously incorporated during filament formation. These molecules may act as cofactors to stabilize the folding of tau during initial filament assembly and/or subsequent seeded aggregation. Indeed, fatty acids induce recombinant tau to form filaments 25 and CTE tau filaments seed the aggregation of three-repeat and four-repeat tau in cultured cells 26 . Moreover, in Niemann-Pick disease type C, the cellular accumulation of cholesterol leads to the formation of abundant filamentous tau inclusions in the brain 27, 28 . By contrast, structures of in vitro-assembled α-synuclein and β2-microglobulin filaments contain similar cavities that are devoid of densities [29] [30] [31] [32] . Sequestration of cellular factors by CTE filaments within the hydrophobic cavity may contribute to their neurotoxicity 33 . The presence of tau inclusions around blood vessels in CTE suggests that cofactors for assembly may initially enter the brain from the periphery after head trauma, or be dependent on peripheral mechanisms. Repetitive head trauma has previously been shown to lead to a transient inflammatory response and compromise of the blood-brain barrier 34 . Although the epidemiology of CTE is not known, it appears probable that brain trauma leads to CTE in only a subset of individuals 35 , which could include those with higher levels of cofactors. These cofactors may, therefore, represent therapeutic targets for the prevention of tau assembly in CTE. Moreover, the stereochemical environment of cofactors within the CTE fold may inform the design of compounds that displace them, destabilize the filament fold or prevent the addition of tau monomers during filament elongation. Incorporation of a compound into a similar cavity in α-synuclein filaments has previously been shown to inhibit assembly 36 . The CTE fold supports the hypothesis that conformers of filamentous tau define distinct tauopathies. We previously showed that tau filaments from Alzheimer's and Pick's diseases adopt different folds [12] [13] [14] , which establishes the existence of molecular conformers. In contrast to Pick's disease, filaments in CTE have the same composition of tau isoforms as in Alzheimer's disease, showing that the same protein sequences can also form different conformers or aggregate strains. The results presented here provide a unifying neuropathological criterion, and confirm that dementia pugilistica and CTE are the same disease. The structures will aid in the design of specific tracer compounds, which are crucial for early diagnosis and thus allow for timely therapeutic intervention.
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METHODS
No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment. Clinical history and neuropathology. The individual who represents our case 1 of CTE is a retired professional American football player, who died aged 67. Our cases 2 and 3 of CTE are individuals who were formerly professional boxers, who died aged 67 and 78, respectively. Case 1 is documented here for the first time, whereas cases 2 and 3 have previously been described 5, 16, [37] [38] [39] [40] . The individual in case 1 played football during high school and college, and in over 30 professional matches during the 1970s. He reported a history of at least 30 concussions, 7 of which were accompanied by a loss of consciousness. During his footballing career, he used the anabolic steroid methandrostenolone (Dianabol). He suffered from memory problems for several years and his family noticed an irritable mood and behavioural outbursts. He also reported muscle weakness. He was able to walk a few steps, but was mostly reliant on a wheelchair. Physical examination confirmed a motor neuron-predominant weakness without prominent upper motor signs. The mother of the individual in case 1 was diagnosed with amyotrophic lateral sclerosis (ALS) in her 80s.
Neuropathologically, all three cases had stage 4 CTE
5
, with abundant silver-positive tau inclusions in the brain (Fig. 1a-c, Extended Data Fig. 1a, b) . By immunoblotting of the sarkosyl-insoluble fraction of the temporal cortex, we observed a pattern consistent with the presence of all six brain tau isoforms [16] [17] [18] (Extended Data Fig. 1d ). Case 1 also had a small number of AT8-positive inclusions in the spinal cord, mostly around blood vessels (Extended Data Fig. 1c) . Inclusions of TAR DNA-binding protein (TDP) of 43 kDa in size (TDP-43) were present in the spinal cord (Extended Data Fig. 1e ). TDP-43 inclusions and ALS are increased in individuals with CTE 41, 42 . As previously described 5, 16, [37] [38] [39] , case 2 had abundant tau and TDP-43 inclusions in both brain and spinal cord (Extended Data Fig. 1a, c, f) . The inclusions were present in separate cells (Extended Data Fig. 1f, top right) . The TDP-43 pathology in the brain was type B 43 . Dipeptide repeat inclusions (poly-GA) were present in the cerebellum (Extended Data Fig. 1f) , which prompted us to sequence C9orf72. We detected a heterozygous hexanucleotide GGGGCC repeat expansion mutation in intron 1 of C9orf72 (more than 145 repeats). Cases 1 and 3 had wild-type numbers of hexanucleotide repeats in both alleles. As previously mentioned 37 , the individual of case 2 had a sibling with ALS. We conclude that case 2 suffered from inherited frontotemporal lobar degeneration (FTLD) and/or ALS, in addition to CTE. Case 3 had abundant tau inclusions in the brain, as previously reported 16, 40 (Extended Data Fig. 1a) . Abundant α-synuclein inclusions were also present in substantia nigra, dorsal motor nucleus of the vagus nerve, locus coeruleus and several other brain regions, confirming a previous study 40 (Extended Data Fig. 1g ). This individual therefore had CTE and Parkinson's disease. Clinical and neuropathological co-morbidities are common in CTE 44 . The spinal cord of case 3 was not available, but there was no reported clinical or family history of ALS. By immunohistochemistry, abundant Aβ plaques were not observed in any of the three cases.
No known mutations in over 50 genes reported to cause Alzheimer's disease, Parkinson's disease, many cases of ALS or frontotemporal dementia were detected in the three cases by next-generation sequencing. The APOE genotypes were: case 1 (ε2/ε3), case 2 (ε3/ε4) and case 3 (ε3/ε3). Case 1 was homozygous, and cases 2 and 3 heterozygous for the TMEM106B variant, rs3173615 (c.554C>G, p.T185S), which has previously been reported to alter the neuropathology of CTE 45 . Case 1 was heterozygous and case 2 homozygous for the T allele at the RS5848 locus in the 3′-untranslated region of GRN. A C>T substitution occurs more frequently in cases of FTLD-TDP than in controls 46 . Extraction of tau filaments. Sarkosyl-insoluble material was extracted from fresh-frozen temporal cortex, as previously described 17 . Approximately 6 g tissue was used for cryo-EM and 0.6 g for immunogold negative-stain electron microscopy (immuno-EM). The pelleted sarkosyl-insoluble material was resuspended in 10 mM Tris-HCl pH 7.4, 800 mM NaCl, 5 mM EDTA and 1 mM EGTA, with a final concentration of 10% (w/v) sucrose at 750 μl/g, followed by centrifugation at 20,100g for 30 min at 4 °C. The resulting supernatants were centrifuged at 100,000g for 1 h at 4 °C. The pellets were resuspended in 20 mM Tris-HCl pH 7.4 containing 100 mM NaCl at 250 μl/g and centrifuged at 100,000g for 30 min at 4 °C. The final pellets were resuspended in buffer at 15 μl/g for cryo-EM and 150 μl/g for immuno-EM. Cryo-EM. Extracted tau filaments were applied to glow-discharged holey carbon grids (Quantifoil Au R1.2/1.3, 300 mesh) and plunge-frozen in liquid ethane using an FEI Vitrobot Mark IV. Images were acquired on a Gatan K2-Summit detector in counting mode using an FEI Titan Krios at 300 kV. A GIF-quantum energy filter (Gatan) was used with a slit width of 20 eV to remove inelastically scattered electrons. Further details are given in Extended Data Table 1 . Helical reconstruction. Movie frames were corrected for gain reference, motion-corrected and dose-weighted using MOTIONCOR2 47 . Aligned, non-dose-weighted micrographs were used to estimate the contrast transfer function (CTF) in Gctf 48 . All subsequent image-processing steps were performed using helical reconstruction methods in RELION 3.0 20, 49 . Filaments were picked manually; type I and type II filaments were subsequently separated by reference-free 2D classification of segments comprising an entire helical crossover (using box sizes of 800 pixels and an inter-box distance of 14 Å). Type I and type II filament segments were re-extracted using box sizes of 270 pixels and an inter-box distance of 14 Å. Reference-free 2D classification was performed and segments contributing to suboptimal 2D class averages discarded. Initial 3D models were constructed de novo from 2D class averages from the case 1 dataset of segments that comprise entire helical crossovers, and low-pass-filtered to 40 Å.
For CTE type I tau filaments from case 1, 3D autorefinement with optimization of the helical twist was performed with a value of 10% for the helical z-percentage parameter, before correcting for per-particle beam-induced motion and defocus using Bayesian polishing and CTF refinement, respectively. We then performed 3D classification with local optimization of helical twist and rise, to remove segments that contributed to suboptimal 3D class averages, and further 3D autorefinement. Following attempted beam-tilt estimation, instead of the axial coma that would be produced by a tilted beam, we observed strong threefold astigmatism in the per-Fourier-pixel average phase-error plot (Extended Data Fig. 8,  top) . Transmission electron microscopes often exhibit optical aberrations-that is, unequal phase delays between the waves that correspond to different image frequencies. These aberrations can always be separated into a symmetrical and an antisymmetrical component: the symmetrical component gives rise to the CTF, and the antisymmetrical component induces phase shifts in the complex amplitudes of the observed image. The threefold astigmatism that we measured is such an antisymmetrical aberration. In a development version of RELION, we modelled this using the first six antisymmetrical Zernike polynomials (radial orders 1 and 2), assuming the effect to be constant across the entire dataset. The coefficients of the Zernike polynomials were estimated so as to minimize the sum of squared per-pixel differences over all pixels and particles between the predicted and the observed particle images. Expressing the aberration in this way enabled us to demodulate the phases of the particle images and thus to correct for the antisymmetrical aberration, which yielded an improvement in resolution from 2.7 to 2.5 Å. In addition to the antisymmetrical aberration, we developed a related method to estimate the symmetrical aberrations. We extended the argument of the CTF sine function in RELION by an offset term that was modelled using the first nine symmetrical Zernike polynomials (radial orders 0, 2 and 4). The coefficients were again estimated so as to minimize the sum of squared differences. Visualization of the per-Fourier-pixel offset term revealed the presence of fourfold astigmatism, which cannot be expressed by the traditional CTF model and which deforms the rings of the CTF from the usually elliptical shape to be slightly square-shaped (Extended Data Fig. 8, bottom) . Correcting for fourfold astigmatism, combined with a larger box size of 400 pixels, led to a resolution of 2.3 Å. Details of the higher-order aberration correction in RELION will be published elsewhere.
For CTE type I tau filaments from cases 2 and 3, 3D classification with local optimization of helical twist and rise was performed to remove segments that contributed to suboptimal 3D class averages, followed by 3D autorefinement with optimization of the helical twist with a value of 10% for the helical z-percentage parameter. For the type II filaments from case 1, CTE type II filaments were separated from paired helical filaments by 3D classification with local optimization of helical twist and rise. For case 2, 3D classification of the type II filaments only identified CTE type II filaments. Three-dimensional autorefinement with optimization of the helical twist with a value of 10% for the helical z-percentage parameter was then performed on the separated filaments. Type II tau filaments from case 3 did not yield reliable 3D reconstructions.
The final reconstructions were sharpened using the standard post-processing procedures in RELION and helical symmetry was imposed using the RELION helix toolbox 20 . Finally, overall resolution estimates were calculated from Fourier shell correlations at 0.143 between two independently refined half-maps, using phase randomization to correct for the convolution effects of a generous, soft-edged solvent mask 50 . Local resolution estimates were obtained using the same-phase randomization procedure, but with a soft spherical mask that was moved over the entire map. For further details, see Extended Data Table 1 .
Model building and refinement. The two cross-β packing stacks and their linking regions were taken from the Alzheimer's disease paired-helical-filament model (RCSB Protein Data Bank (PDB) accession number 6HRE). The β-helix and its preceding and proceeding regions were built de novo into the 2.3 Å resolution reconstruction of CTE type I tau filaments from case 1 using COOT 51 . Water molecules and generic fused ring compounds (PubChem CID 1107) were added in COOT. The new model was then refined against the CTE type I and type II filament reconstructions from case 1 using targeted real-space refinement in COOT. The models were subsequently translated to give stacks of three consecutive monomers to preserve nearest-neighbour interactions for the middle chains in
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subsequent Fourier-space refinements in REFMAC 52 . Local symmetry restraints were imposed to keep all β-strand rungs identical. Side-chain clashes were detected using MOLPROBITY 53 and corrected by iterative cycles of real-space refinements in COOT and Fourier-space refinements in REFMAC. Separate model refinements were performed against single half-maps, and the resulting models were compared with the other half-maps to confirm the absence of overfitting. The final models were stable in refinements without additional restraints. Further details are given in Extended Data Table 1 . Immunolabelling, histology and silver staining. Immuno-EM was carried out as previously described 13 . Primary antibodies were BR136 13 (raised against tau residues 244-257), anti-4R 54 (raised against tau residues 275-291, with D279; Cosmo Bio CAC-TIP-4RT-P01), BR135 55 (raised against tau residues 323-335) and TauC4 56 (raised against tau residues 354-369), all used at 1:50. Images were acquired at 11,000×, with a defocus value of −1.4 μm with a Gatan Orius SC200B CCD detector using a Tecnai G2 Spirit at 120 kV. To distinguish non-specific background from specific labelling, we only considered filaments with more than six gold beads to be positively labelled.
Immunoblotting was carried out as previously described 13 . Samples were resolved on 4-20% Tris-glycine gels (Novex), and the primary antibodies were diluted in PBS plus 0.1% Tween 20 and 1% bovine serum albumin (BSA). Primary antibodies were BR133 55 , used at 1:4,000, BR136 13 , used at 1:1,000, anti-4R 54 (Cosmo Bio CAC-TIP-4RT-P01), used at 1:2,000, BR135 55 , used at 1:4,000 and TauC4
56
, used at 1:2,000, BR134 55 , used at 1:4,000 and AT8 (specific for pS202 and pT205 tau; Thermo Fisher Scientific MN2010), used at 1:1,000.
Histology and immunohistochemistry were carried out as previously described 57 . Brain sections were 8-μm thick and were counterstained with haematoxylin. Primary antibodies were AT8 (Thermo Fisher Scientific MN1020), used at 1:300, AT100 (specific for pT212, pS214 and pT217 tau, Thermo Fisher Scientific MN1060), used at 1:400, anti-4R 54 (Cosmo Bio CAC-TIP-4RT-P01), used at 1:400, RD3 (Merck 05-803), used at 1:3,000, anti-phospho-TDP-43 (specific for pS409 and pS410 TDP-43; Cosmo Bio CAC-TIP-PTD-M01), used at 1:1,000, SYN 58 (specific for α-synuclein residues 119-137), used at 1:300 and anti-poly-GA (Cosmo Bio CAC-TIP-C9-P01), used at 1:300. Sections were silver-impregnated using the method of Gallyas-Braak to visualize inclusions 59, 60 . Whole-exome sequencing. Target enrichment made use of the SureSelectXT human all-exon library (V6, 58 Mb, Agilent) and high-throughput sequencing was carried out using a HiSeq4000 (2 × 75-bp paired-end configuration, Illumina). Bioinformatics analyses were performed as previously described 61 . Whole-genome sequencing. Sequencing libraries were prepared using 100 ng high-quality genomic DNA from cerebellum using the Illumina Nextera DNA Flex Library Prep Kit, and assessed using a Qubit and Agilent Bioanalyzer. Highthroughput sequencing was carried out on multiple libraries pooled in equal molarity using a NovaSeq6000 (150-bp paired-end configuration, Illumina) and aligned to the human reference genome GRCh38 using BWA and Bwakit (v.0.7.15). ExpansionHunter was applied to estimate expansion numbers of short tandem repeats (v.2.5.5) and germline variants were identified with Strelka2 (v.2.9.9), with default parameters for whole-genome sequence data. The variants were annotated for their effects with ANNOVAR 62 . C9orf72 hexanucleotide repeat expansion. Repeat-primed polymerase chain reaction was used to determine the number of GGGGCC hexanucleotide repeats in the first intron of C9orf72 (Asuragen AmplideX PCR/CE C9orf72 kit). Internal standards were analysed along with samples to evaluate assay performance. Repeat numbers of up to 25 repeats were determined with an accuracy of ±1 repeat, and repeat numbers greater than 25 were determined with an accuracy of ±3 repeats. Ethical review board and informed consent. The studies carried out at Indiana University and the University of Kansas were approved through the institutional review process at each University. Informed consent was obtained from the patients' next of kin. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
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